Kiromic Biopharma Alpha and Beta Analysis
| KRBPDelisted Stock | USD 2.68 0.07 2.55% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Kiromic Biopharma. It also helps investors analyze the systematic and unsystematic risks associated with investing in Kiromic Biopharma over a specified time horizon. Remember, high Kiromic Biopharma's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Kiromic Biopharma's market risk premium analysis include:
Beta (2.20) | Alpha 0.0822 | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Kiromic |
Kiromic Biopharma Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Kiromic Biopharma market risk premium is the additional return an investor will receive from holding Kiromic Biopharma long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Kiromic Biopharma. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Kiromic Biopharma's performance over market.| α | 0.08 | β | -2.2 |
Kiromic Biopharma Fundamentals Vs Peers
Comparing Kiromic Biopharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Kiromic Biopharma's direct or indirect competition across all of the common fundamentals between Kiromic Biopharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as Kiromic Biopharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Kiromic Biopharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing Kiromic Biopharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Kiromic Biopharma to competition |
| Fundamentals | Kiromic Biopharma | Peer Average |
| Return On Equity | -11.3 | -0.31 |
| Return On Asset | -0.92 | -0.14 |
| Current Valuation | 9.55 M | 16.62 B |
| Shares Outstanding | 1.18 M | 571.82 M |
| Shares Owned By Insiders | 3.91 % | 10.09 % |
| Shares Owned By Institutions | 68.00 % | 39.21 % |
| Number Of Shares Shorted | 45.74 K | 4.71 M |
Kiromic Biopharma Opportunities
Kiromic Biopharma Return and Market Media
The Stock received some media coverage during the period. Price Growth (%) |
| Timeline |
1 | Kiromic BioPharma, Inc. Sees Large Increase in Short Interest | 05/03/2023 |
2 | Should You Hold Kiromic Biopharma Inc Stock Tuesday Morning - InvestorsObserver | 05/16/2023 |
3 | Kiromic Biopharma Shares Down 12 percent After Stock Offering Prospectus | 06/30/2023 |
About Kiromic Biopharma Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Kiromic or other delisted stocks. Alpha measures the amount that position in Kiromic Biopharma has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Kiromic Biopharma Upcoming Company Events
As portrayed in its financial statements, the presentation of Kiromic Biopharma's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Kiromic Biopharma's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Kiromic Biopharma's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Kiromic Biopharma. Please utilize our Beneish M Score to check the likelihood of Kiromic Biopharma's management manipulating its earnings.
| 13th of November 2023 Upcoming Quarterly Report | View | |
| 30th of September 2023 Next Fiscal Quarter End | View |
Build Portfolio with Kiromic Biopharma
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Other Consideration for investing in Kiromic Stock
If you are still planning to invest in Kiromic Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kiromic Biopharma's history and understand the potential risks before investing.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |